In the context of cancer, CCL19 has been reported to promote antitumor immunity by facilitating immune cell infiltration into the TME and enhancing T cell activation.[51–53] CX3CL1, also known as fractalkine, is a unique chemokine that exists both as a soluble molecule and as a membrane-bound protein. The gene discussed is CCL19; the disease is cancer.